November 5, 2013
Eisai President Haruo Naito Eisai’s group sales in the six months through September grew 6.6% from a year ago to 307,481 million yen as its anticancer agent Halaven (eribulin) and other growth-driver portfolios performed strongly to more than offset the...read more